We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 204

Federal Circuit finds Solvay HFC patent invalid under 102(g)

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • February 20 2014

In Solvay S.A. V. Honeywell International Inc., the Federal Circuit upheld the district court's finding that Solavay's HFC patent was invalid under

Takeda Prevacid SoluTab patent valid, but not infringed

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • February 24 2014

In Takeda Pharmaceutical Company Ltd. v. Zydus Pharmaceuticals USA, Inc., the Federal Circuit reversed the district court's finding that Zydus's

Do the USPTO 101 guidelines violate international trade agreements?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 9 2014

One advantage of being a blogger in the relatively small world of patents is that I have gotten to know practitioners in other countries who also

Federal Circuit refuses to find implied license for Endo Opana patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 7 2014

In Endo Pharmaceuticals, Inc. v. Actavis, Inc., the Federal Circuit reversed the district court's decision denying Endo's motion for summary judgment

Federal Circuit issues remand in ten year reexamination proceeding

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • February 18 2014

In Tempo Lighting, Inc. v. Tivoli, LLC, the Federal Circuit vacated the decision of the U.S. Patent Office Patent Trial and Appeal Board that had

Split Federal Circuit hews to de novo claim construction review

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • February 28 2014

In a six-four en banc decision in Lighting Ballast Control LLC v. Philips Electronics North Am. Corp., a divided Federal Circuit confirmed its

Do pharmaceutical compositions have patent subject matter eligibility under the new USPTO guidelines?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 10 2014

The USPTO's new patent subject matter eligibility guidelines (the "Guidelines") include examples that apply the multi-factored analysis mandated by

Federal Circuit holds computer-implemented method claims invalid under Section 101

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • February 4 2014

Although SmartGene, Inc. v. Advanced Biological Laboratories, SA is a non-precedential Federal Circuit decision, it could be interesting for that

Federal circuits finds broad range anticipates narrower range

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 1 2012

In ClearValue, Inc. v. Pearl River Polymers, Inc., the Federal Circuit found that a jury verdict of validity was not supported by substantial evidence, and so reversed the district court’s decision denying Pearl River’s motion for judgment as a matter of law (JMOL

Judge Rader explains 35 USC 101 in Ultramercial v Hulu

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 24 2013

In the June 21, 2013 Federal Circuit decision in Ultramercial, Inc. v. Hulu, LLC, the court again reversed the district court's finding that the